Clinical trial · Observational
Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This investigation was carried out to analyze and compare the salivary paxillin levels between oral premalignant and malignant lesions (OPMLs), OSCC and the healthy controls in order to assess its potential role as a biomarker of oral cancer aiming for early diagnosis and better prognosis of OSCC. Methods: Forty-five patients, ranging in age from thirty to seventy-five, were divided into three groups: fifteen patients with OPMLs (lichen planus, leukoplakia), fifteen patients with OSCC, and fifteen controls who were in general well. Paxillin was identified in saliva samples by using an ELISA kit.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paxillin biomarker | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group A
- description
- fifteen patients with OPMLs (lichen planus, leukoplakia)
- interventionNames
- Diagnostic Test: Paxillin biomarker
- label
- Group B
- description
- fifteen patients with OSCC
- interventionNames
- Diagnostic Test: Paxillin biomarker
- label
- Group C
- description
- fifteen systemically healthy control subjects
- interventionNames
- Diagnostic Test: Paxillin biomarker
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients with leukoplakia patients with atropic lichen planus patients with bullous erosive lichen planus patients with squamous cell carcinoma Exclusion Criteria: * patients with papular lichen planus patients with underlying systemic disease leukemic patients smokers hepatic patients
References
Publications (1)
- DERIVEDHussine AA, Selim K, Shaker O, Kamal Y. Evaluation of the levels of salivary paxillin in oral potentially malignant disorders and malignant lesions. BMC Oral Health. 2024 Jul 24;24(1):834. doi: 10.1186/s12903-024-04569-z. PMID 39048985